Cabaletta Bio, Inc. (CABA)
Stock Price:
$11.57 USD
-0.65 (-5.32%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
278.14M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-25.69M |
| Shares Out |
24.04M |
| EPS (ttm) |
-10.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$11.57 |
| Previous Close |
$12.22 |
| Change ($) |
-0.65 |
| Change (%) |
-5.32% |
| Day's Open |
12.11 |
| Day's Range |
11.20 - 12.49 |
| Day's Volume |
43,383 |
| 52-Week Range |
5.51 - 19.63 |
More Stats
| Market Cap |
278.14M |
| Enterprise Value |
158.34M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
24.04M |
| Float |
17.02M |
| EPS (basic) |
2.42 |
| EPS (diluted) |
-10.97 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.09M |
| Short Ratio |
13.00 |
| Short % of Float |
6.40% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.24 |
| Revenue |
n/a |
| Operating Income |
-26.98M |
| Net Income |
-25.69M |
| Free Cash Flow |
n/a |
| Net Cash |
119.80M |
| Net Cash / Share |
4.98 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-16.39% |
| ROE |
-25.61% |
| ROIC |
-637.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$21.67*
(87.29% upside)
Low
20.0
Current: $11.57
High
25.0
Target: 21.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -18.68 | -6.19 |
| Net Income | -16.94 | -12.20 |
| Shares Outstanding | 24.03 | 1.78 |
| Earnings Per Share | -4.07 | -6.87 |
| Operating Cash Flow | -16.05 | -4.66 |
| Capital Expenditures | -0.69 | - |
| Free Cash Flow | -16.74 | -4.66 |
| Cash & Equivalents | 136 | 33.02 |
| Net Cash / Debt | 136 | 33.02 |
| Assets | 141 | 34.17 |
| Liabilities | 3.15 | 44.86 |
| Book Value | 138 | -10.69 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cabaletta Bio, Inc. |
| Country |
United States |
| Employees |
31 |
| CEO |
Steven Nichtberger |
Stock Information
| Ticker Symbol |
CABA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CABA |
| IPO Date |
October 25, 2019 |
Description
Cabaletta Bio, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.